ARTICLE | Translation in Brief
Second chance for grantees
Leidos promises a second life for unfunded NIH proposals
April 28, 2016 7:00 AM UTC
NIH has launched a pilot program with Leidos Holdings Inc. (NYSE:LDOS) to answer the question: is there life after grant rejection?
The academic community has long groused about funding limitations through NIH, and even with the $2 billion increase in funding for FY16, many highly scored grant proposals get underfunded or passed over altogether. With initial backing from NIH, Leidos developed the Online Partnership to Accelerate Research (OnPAR), a pilot tool to connect researchers who have strong, but NIH-rejected, proposals with funding bodies such as non-profits or pharmas looking for specific kinds of research...